Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

mylan s.p.a. - cisatracurio - cisatracurio

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

orion corporation - formoterolo e budesonide - formoterolo e budesonide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

elpen pharmaceutical co. inc. - formoterolo e budesonide - formoterolo e budesonide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

boehringer ingelheim international gmbh - indacaterolo e glicopirronio bromuro - indacaterolo e glicopirronio bromuro

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

accord healthcare, s.l.u. - glicopirronio - glicopirronio

Unione Europea - italiano - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - farmaci per le malattie respiratorie ostruttive, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Unione Europea - italiano - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - farmaci per le malattie respiratorie ostruttive, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - salbutamolum - sirup - salbutamolum 2 mg ut salbutamoli sulfas, natrii citras dihydricus, acidum citricum monohydricum, hypromellosum, e 211 10 mg, saccharinum natricum, aromatica (orange), natrii chloridum, aqua purificata, q.s. ad solutionem pro 5 ml, natrium 5.6 mg. - bronchospasmolytikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - salbutamolum - soluzione concentrata per aerosolgeräte - salbutamolum 5 mg ut salbutamoli sulfas, benzalkonii chloridum 0.1 mg, acidum sulfuricum, aqua purificata, ad solutionem pro 1 ml. - bronchospasmolytikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

orion pharma ag - salbutamolum - polvere per inalazione - salbutamolum 100 µg di salbutamoli sulfas, lactosum monohydricum, per la polvere per le dosi, dosi per una nave di 200. - bronchospasmolytikum - synthetika